Board of Directors

Ian Ihnatowycz , , , Chairman

Mr. Ihnatowycz is the Chairman of the Board of Directors and currently serves as the President and Chief Executive Officer of First Generation Capital Inc., a private investment holding company. Mr. Ihnatowycz previously served as President and Chief Executive Officer of Acuity Investment Management Inc. and Acuity Funds Ltd. from 1990 until its sale in 2011. Mr. Ihnatowycz has served on the board of directors of a number of public and private companies and a variety of professional and not-for-profit organizations, including the Royal Conservatory. Additionally, Mr. Ihnatowycz is a member of the Ivey Advisory Board and the Ian. O. Ihnatowycz Institute for Leadership Advisory Board, both at the Ivey Business School.

Tom Rossi , , , President and Chief Executive Officer

Tom Rossi serves as President and Chief Executive Officer of Acerus Pharmaceuticals Corporation. Mr. Rossi has over 25 years of experience in the pharmaceutical industry in Canada and abroad. Previously, Mr. Rossi held a variety of leadership positions within Novartis. Most recently, Mr. Rossi was CEO and Country President for Novartis Pharmaceuticals Canada and served as a member of the Rx&D Board of Directors. Prior to returning to Canada, Mr. Rossi was CEO and Country President for Novartis Pharmaceuticals Belgium and was a member of the Novartis Pharma European Executive Committee. Mr. Rossi joined Novartis from Merck Canada and began his healthcare career with Johnson & Johnson. Mr. Rossi holds a Bachelor of Science degree in Microbiology and Immunology from McGill University. In addition, Mr. Rossi received a Master of Business Administration from the John Molson School of Business (Concordia University) focused on Pharmaceutical Marketing.

Norma Beauchamp , ,

Ms. Beauchamp is the President and Chief Executive Officer of Cystic Fibrosis Canada. An accomplished business and non-profit leader, she has held three decades of senior leadership positions in Canada and Germany, including executive positions at Genzyme, Bayer, Sanofi and the Canadian Foundation for Women’s Health. Ms. Beauchamp has served on the boards of the St. Joseph’s Health Centre Foundation, Providence Healthcare Foundation and the Breast Cancer Society of Canada, and is also a passionate patient advocate, working with patient and healthcare organizations to enhance access to care. Ms. Beauchamp completed the University of Toronto’s Rotman School of Management Directors Education Program (ICD.D) in 2009 and graduated from Bishop’s University with a Bachelor of Business Administration in Marketing.

Stephen Gregory , ,

Mr. Gregory is President, Chairman and the controlling shareholder of IsaiX Technologies, a privately held company headquartered in Montreal, with offices in the United States. IsaiX Technologies works extensively across a wide variety of industry segments and has ongoing business transactions with more than 200 global brands in the pharmaceutical, health, finance, banking and insurance sectors. IsaiX Technologies provides and implements its clients with human development programs, medical writing and essential physician scheduling platforms. Mr. Gregory is the President of the Quebec Chapter of Canada Company and is a member of its Executive Committee. Mr. Gregory also spearheads charitable endeavours for the children of Canadian soldiers serving overseas.

Borys Chabursky , ,

Mr. Borys Chabursky specializes in strategic planning, fundraising, financial management and business development for biotechnology, medical device, imaging and oncology companies and science and technology incubators in both the public and private sector. As the founder and Chairman of Shift Health, he has overseen the successful completion of over 500 life sciences assignments for more than 300 clients in North America, Europe and the Middle East; the development of compelling business cases and implementation plans that have helped leverage over $1B in financing from private and public sector resources; and the creation and facilitation of more than 50 public-private partnerships in biomedical research, infrastructure development and global health. Mr. Chabursky has worked closely with industry thought leaders, large pharmaceutical companies, government agencies, hospital boards and healthcare networks. He has also provided interim management for seven start-up companies and angel financing for ten new start-up ventures. With his experience spearheading large-scale, multi-stakeholder, global initiatives, Mr. Chabursky often serves as an advisor to influencers and developers of government policy.

Luc Mainville , ,

Mr. Mainville is currently founder and majority shareholder of LUMA Capital, a private investment holding company, as well as LUMA Life, a private company focusing on the development and commercialization of innovative medical devices. Previously, Mr. Mainville served as Executive Vice President for Cardiome Pharma Corp. as well as President and Chief Executive Officer of Neopharm Labs Inc. and prior to that LAB Research Inc. He has gained considerable experience throughout his career in senior management, operational and corporate finance roles, and served as a director for a number of public and private companies in the biotechnology and pharmaceutical sectors. In particular, Mr. Mainville has led more than 30 mergers and acquisitions, as well as served as Chair of the Audit Committee for a number of Boards, including that of Enobia Pharma, Powertech Corporation, Cyplasin Biomedical, Alethia BioTherapeutics and Bioaxone Therapeutics. He served as Vice-Chairman of BioteCanada, and also teaches corporate governance and mergers and acquisitions courses at McGill University in Montreal, Quebec. Prior to his career in the life science industry, Mr. Mainville was a Senior Vice President and Partner at KPMG.